Striatal extracellular dopamine levels and behavioural reversal in MPTP-lesioned mice

被引:9
作者
Kirchhoff, Jeppe [1 ,2 ]
Mork, Arne [1 ]
Brennum, Lise T. [2 ]
Sager, Thomas N. [2 ]
机构
[1] H Lundbeck & Co AS, Dept Neurophysiol, DK-2500 Copenhagen, Denmark
[2] H Lundbeck & Co AS, Dept In Vivo Neurobiol, DK-2500 Copenhagen, Denmark
关键词
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-dihydroxy-L-phenylalanine; dopamine; in-vivo microdialysis; Parkinson's disease; striatum; TREATED-MOUSE MODEL; PARKINSONS-DISEASE; PERFORMANCE-TEST; RECEPTORS; RECOVERY;
D O I
10.1097/WNR.0b013e32832984d6
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Intoxication induced by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in mice results in a significant loss of nigrostriatal dopamine (DA) neurons. This is accompanied by a change in behavioural phenotype that can be reversed by L-DOPA (3,4-dihydroxy-L-phenylalanine) treatment. Here, we examined the extracellular levels of DA, behavioural deficits and the response to L-DOPA treatment in severely intoxicated mice. The MPTP intoxication produced more than a 90% reduction in tissue DA and a 65% decline in extracellular DA levels. In-vivo binding did not show any increased raclopride binding to the D-2 receptor. Administration of L-DOPA, 5 or 20 mg/kg (subcutaneously), significantly increased dialysate DA levels and both doses of L-DOPA reversed the behavioural deficit Interestingly, only 5 mg/kg L-DOPA normalized DA levels to 56% of controls showing that only a minor increase in DA levels is sufficient to yield motor recovery. NeuroReport 20:482-486 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:482 / 486
页数:5
相关论文
共 18 条
  • [1] SOME ATYPICAL NEUROLEPTICS INHIBIT [H-3] SCH 23390 BINDING INVIVO
    ANDERSEN, PH
    NIELSEN, EB
    GRONVALD, FC
    BRAESTRUP, C
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 120 (01) : 143 - 144
  • [2] Experimental models of Parkinson's disease
    Beal, MF
    [J]. NATURE REVIEWS NEUROSCIENCE, 2001, 2 (05) : 325 - 332
  • [3] Behavioral recovery in MPTP-treated monkeys:: Neurochemical mechanisms studied by intrastriatal microdialysis
    Boulet, Sabrina
    Mounayar, Stephanie
    Poupard, Annie
    Bertrand, Anne
    Jan, Caroline
    Pessiglione, Mathias
    Hirsch, Etienne C.
    Feuerstein, Claude
    Francois, Chantal
    Feger, Jean
    Savasta, Marc
    Tremblay, Leon
    [J]. JOURNAL OF NEUROSCIENCE, 2008, 28 (38) : 9575 - 9584
  • [4] Elsworth JD, 2000, NEUROSCIENCE, V95, P399
  • [5] FRANKLIN KBJ, 1997, MOUSE BRAIN
  • [6] Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D2 receptors in the mouse striatum
    Ishiwata, K
    Koyanagi, Y
    Abe, K
    Kawamura, K
    Taguchi, K
    Saitoh, T
    Toda, J
    Senda, M
    Sano, T
    [J]. JOURNAL OF NEUROCHEMISTRY, 2001, 79 (04) : 868 - 876
  • [7] Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: A suggested solution based on in vivo occupancy
    Kapur, S
    Vanderspek, SC
    Brownlee, BA
    Nobrega, JN
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (02) : 625 - 631
  • [8] Peculiarities of L-DOPA treatment of Parkinson's disease
    Kostrzewa, RM
    Nowak, P
    Kostrzewa, JP
    Kostrzewa, RA
    Brus, R
    [J]. AMINO ACIDS, 2005, 28 (02) : 157 - 164
  • [9] Neuroprotective strategies in Parkinson's disease -: An update on progress
    Mandel, S
    Grünblatt, E
    Riederer, P
    Gerlach, M
    Levites, Y
    Youdim, MBH
    [J]. CNS DRUGS, 2003, 17 (10) : 729 - 762
  • [10] Behavioral models of Parkinson's disease in rodents: A new look at an old problem
    Meredith, Gloria E.
    Kang, Un Jung
    [J]. MOVEMENT DISORDERS, 2006, 21 (10) : 1595 - 1606